Preparation and in vitro/in vivo characterization of curcumin microspheres intended to treat colon cancer

Journal of Pharmacy and Bioallied Sciences

Volumn 4, Issue 2, 2012, Pages 164-171

  Madhavi, M ^a   Madhavi, K ^b   Jithan, A V ^c  

^a Priyadarshini Yashodhara College of Pharmacy   (India)

^b Care College of Pharmacy   (India)

^c Mother Teresa College of Pharmacy   (India)

Author keywords

Colon targeting; curcumin; eudragit S100; microspheres; pH sensitive

Indexed keywords

CURCUMIN; EUDRAGIT; MICROSPHERE; POLYMER; SOLVENT;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COLON CANCER; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SYNTHESIS; EVAPORATION; GASTROINTESTINAL TRANSIT; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MALE; MAXIMUM PLASMA CONCENTRATION; MICROTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; ROOM TEMPERATURE; SOLUBILITY;

RATTUS;

EID: 84859784591     PISSN: None     EISSN: 09757406     Source Type: Journal    
DOI: 10.4103/0975-7406.94825     Document Type: Article

References (29)

1. Krishnaiah YSR, Satyanarayana S. In: Advances in controlled and novel drug delivery: Colon specific drug delivery systems. New Delhi: CBS Publishers and Distributors; 2001. p. 89-119.
2. Kinget R, Kalala W, Vervoort L, van den Mooter G. Colonic drug targeting. J Drug Target 1998;6:129-49.
3. Jain D, Panda AK, Majumdar DK. Eudragit S100 entrapped insulin microspheres for oral delivery. AAPS PharmSciTech 2005;6:E100-7.
4. Woo JS, Piao MG, Li DX, Ryu D, Choi JY, Kim J, et al. Development of cyclosporin A-loaded hyaluronic microsphere with enhanced oral bioavailability. Int J Pharm 2007;345:134-41.
5. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002;97:72-81.
6. Johnson JJ, Mukhtar H. Curcumin for chemoprevention of colon cancer. Cancer Lett 2007;255:170-81.
7. Chauhan DP. Chemotherapeutic potential of curcumin for colorectal cancer. Curr Pharm Des 2002;8:1695-706.
8. Chen A, Xu J, Johnson AC. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene 2006;25:278-87.
9. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003;23:363-98.
10. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007;4:807-18.
11. Ireson CR, Jones DJ, Orr S, Coughtrie MW, Boocock DJ, Williams ML, et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 2002;11:105-11.
12. Sharma RA, Steward WP, Gescher AJ. Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol 2007;595:453-70.
13. Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci 2003;6:33-66.
14. Sarasija S, Hota A. Colon-specific drug delivery systems. Indian J Pharm Sci 2000;62:1-8.
15. Vijaya R, Prabhakaran L, Purushothaman M. Colon targeted drug delivery system- an overview. Pharma infonet 2010;8.
16. Vyas SP, Khar RK. Systems for colon specific delivery. In: Controlled drug delivery: concepts and advances. New Delhi: Vallabh Prakashan; 2005. p. 218-53.
17. Asghar LF, Chandran S. Multiparticulate formulation approach to colon specific drug delivery: Current perspectives. J Pharm Pharm Sci 2006;9:327-38.
18. Prajakta D, Ratnesh J, Chandan K, Suresh S, Grace S, Meera V, et al. Curcumin loaded pH-sensitive nanoparticles for the treatment of colon cancer. J Biomed Nanotechnol 2009;5:445-55.
19. Basu SK, Adhiyaman R. Preparation and characterization of nitrendipine loaded Eudragit RL 100 microspheres prepared by an emulsion-solvent evaporation method. Trop J Pharm Res 2008;7:1033-41.
20. Sunil KJ, Gopal R, Saraf DK, Agrawal GP. The preparation and evaluation of albendazole microspheres for colonic delivery. Pharm Tech 2004;28:66-71.
21. Gogu PK, Jithan AV. Preparation and in vitro/in vivo characterization of spray dried microsphere formulation encapsulating 4-chlorocurcumin. Indian J Pharm Sci 2010;72:346-52.
22. Paharia A, Yadav AK, Rai G, Jain SK, Pancholi SS, Agrawal GP. Eudragitcoated pectin microspheres of 5-fluorouracil for colon targeting. AAPS PharmSciTech 2007;8:12.
23. Heath DD, Pruitt MA, Brenner DE, Rock CL. Curcumin in plasma and urine: quantitation by high-performance liquid chromatography J Chromatogr B Analyt Technol Biomed Life Sci 2003;783:287-95.
24. Rahman Z, Kohli K, Zhang SQ, Khar RK, Ali M, Charoo NA, et al. In vivo evaluation in rats of colon-specific microspheres containing 5-fluorouracil. J Pharm Pharmacol 2008;60:615-23.
25. Suresh Kumar R, Munikumar, Ganesh GN, Jawahar J, Nagasamyvenkatesh D, Senthil V, et al. Formulation and evaluation of pectin- hydroxypropylmethylcellulose coated curcumin pellets for colon delivery. Asian J Pharm 2009;3:138-42.
26. Dandagi PM, Mastiholimath VS, Gadad AP, Kulkarni AR, Konnur BK. pH-sensitive mebeverine microspheres for colon delivery. Indian J Pharm Sci 2009;71:464-8.
27. Sanphui P, Rajesh Goud N, Khandavalli UB, Bhanoth S, Nangia A. New polymorphs of curcumin. Electronic Supplementary Material (ESI) for Chemical Communications. United Kingdom: The Royal Society of Chemistry; 2011. p. S1-12.
28. Cifty K, Groves MJ. Delivery of antitumor compounds, to the rat colon: in vitro and in vivo evaluation. Int J Pharm 1996;145:157-64.
29. Jose S, Dhanya K, Cinu TA, Aleykutty NA. Multiparticulate system for colon targeted delivery of ondansetron. Indian J Pharm Sci 2010;72:58-64.